Does Ecallantide work?
Yes, in two controlled trials of 72 and 96 people.
Approval was based on two randomized, double-blind, placebo-controlled trials, EDEMA3 (n=72, cited here) and EDEMA4 (n=96), both showing faster symptom relief than placebo during acute attacks. The trials were small by the standards of common diseases, but hereditary angioedema is rare and two consistent placebo-controlled trials meet the bar for A. 12
EDEMA3 randomized 72 patients having a moderate-to-severe attack. They got a single dose of ecallantide or placebo under the skin. At four hours, the median treatment outcome score was 50 on ecallantide and 0 on placebo. This score is a patient-rated measure of improvement. The median symptom severity score fell by 1.0 point versus 0.5. Both differences were statistically significant. The label reports the same trial as means of 63 versus 36 and 1.1 versus 0.6. 12
EDEMA4 was the second phase 3 trial. It enrolled 96 patients and found the same pattern. Symptom severity fell more at four hours (0.8 versus 0.4). The treatment outcome score was higher (53 versus 8). The FDA approved the drug on the two trials together. They covered 143 unique patients, since some took part in both. 2
Evidence checklist
- Randomised controlled trial EDEMA3 and EDEMA4 placebo-controlled
- Human study over 100 people Largest trial had 96 patients
- More than one research group Trials from one program, sponsor-run
- Clinical outcomes, not surrogate markers Attack symptom relief measured
- Human safety data beyond case reports Anaphylaxis rate from 255 treated patients
Read the full Ecallantide page
More on Ecallantide
Citations
Reference information only, not medical advice. Drawn from the Ecallantide article, fact-checked against the cited sources. No dosing anywhere on this site.